Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy

BACKGROUND: To evaluate the survival benefit of neoadjuvant chemotherapy (NAC) in pathologic T2N0 or less patients. METHODS: A total of 526 patients with less than pT2N0 underwent radical cystectomy. Patients were divided into three groups: non-NAC, those who did not receive NAC; partial NAC, those...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuk, Hyeong Dong, Jeong, Chang Wook, Kwak, Cheol, Kim, Hyeon Hoe, Ku, Ja Hyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354338/
https://www.ncbi.nlm.nih.gov/pubmed/32676410
http://dx.doi.org/10.21037/tau-19-705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354338/
https://www.ncbi.nlm.nih.gov/pubmed/32676410
http://dx.doi.org/10.21037/tau-19-705

Ejemplares similares